First Twenty-Five Percent of Subjects in Provectus’ Phase 2 Melanoma Clinical Trial Treated
News Jul 08, 2008
Provectus Pharmaceuticals, Inc. has announced that the first twenty-five percent (20 of 80) of melanoma subjects have been treated in Provectus Pharmaceuticals’ Phase 2 clinical trial of PV-10.
Additional subjects are being evaluated for eligibility for entrance into the trial or are awaiting treatment at the two active centers in Brisbane and Sydney, Australia.
In addition, Provectus anticipates opening the first United States site for the trial in the very near future. Currently, Provectus is also sponsoring Phase 2 trials for psoriasis and atopic dermatitis in New York and Florida.
In Australia, the trials are currently being conducted at the Sydney Melanoma Unit under the supervision of John F Thompson, MD, and at the Princess Alexandra Hospital in Brisbane, Queensland, under Mark Smithers, MD.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018